Skip to main content

Table 2 Summary of the dose volume histogram analysis for the organs at risk for the node positive patients

From: Treatment planning comparison of volumetric modulated arc therapy employing a dual-layer stacked multi-leaf collimator and helical tomotherapy for cervix uteri

ParameterObjectiveHalcyon (H)Helical Tomotherapy (HT)Difference (H-HT)p
Bowel
 Mean [Gy]Minimise21.2 ± 3.121.1 ± 2.80.1 ± 0.90.82
 D1% [Gy]≤57.548.8 ± 1.747.4 ± 1.31.4 ± 0.7< 0.001
 V40Gy [cm3]≤250 a226.3 ± 35.9258.9 ± 60.5−32.6 ± 34.30.01
 V30Gy [cm3]≤500 a413.4 ± 58.9472.7 ± 90.0−59.4 ± 53.50.01
 V15Gy [cm3]≤700 b1557.2 ± 359.91279.7 ± 296.5277.4 ± 188.60.01
Sigmoid
 D1% [Gy]≤57.550.5 ± 3.749.4 ± 3.81.1 ± 2.10.11
Bladder
 D1% [Gy]≤57.548.8 ± 2.247.0 ± 1.11.8 ± 1.80.01
 V40Gy [%]≤75 a60.0 ± 10.863.6 ± 16.6−3.6 ± 7.50.16
 V30Gy [%]≤85 a76.9 ± 7.177.0 ± 12.5−0.1 ± 9.20.96
Rectum
 D1% [Gy]≤57.548.1 ± 1.346.9 ± 0.71.2 ± 1.80.05
 V40Gy [%]≤85 a66.6 ± 20.572.8 ± 21.7−6.2 ± 11.20.11
 V30Gy [%]≤95 a81.9 ± 12.789.7 ± 14.7−7.8 ± 12.20.07
Spinal Cord
 D1% [Gy]≤48.025.1 ± 17.925.6 ± 16.5−2.4 ± 4.40.12
Left Fem. Head
 D1% [Gy]≤50.038.1 ± 3.639.4 ± 1.6−1.3 ± 3.20.24
 Mean [Gy]b16.4 ± 2.713.8 ± 2.52.6 ± 3.10.001
Right Fem. Head
 D1% [Gy]≤50.036.3 ± 4.641.7 ± 2.9−5.4 ± 2.5< 0.001
 Mean [Gy]b16.1 ± 2.312.6 ± 1.33.5 ± 1.9< 0.001
Left Kidney
 Mean [Gy]≤156.9 ± 5.07.5 ± 5.1−0.6 ± 1.50.22
Right Kidney
 Mean [Gy]6.6 ± 4.87.1 ± 4.2− 0.5 ± 2.10.52
Body
 D1% [Gy]≤58.953.2 ± 1.449.9 ± 3.73.3 ± 4.1< 0.001
 CI36Gy< 1.6 b1.6 ± 0.22.0 ± 0.1−0.4 ± 0.2< 0.001
 CI43Gy< 1.1 b1.1 ± 0.11.3 ± 0.1−0.2 ± 0.1< 0.001
 CIPaddickb0.87 ± 0.040.90 ± 0.07−0.03 ± 0.080.01
 CIPaddick_SIBb0.71 ± 0.080.78 ± 0.15−0.07 ± 0.100.05
  1. Vx%: volume receiving at least x% of the dose. Dx%: dose received by at least x% of the volume
  2. a: soft constraints, expected to be fulfilled in 70–80% of the patients according to EMBRACE II guidelines
  3. b: not included as optimisation constraint